Iron Replacement Roundup

Restricted access

In Corona, Calif., Watson Pharmaceuticals announced it would continue to sell its iron deficiency treatment, Ferrlecit, in the United States until the end of the year. A Swiss arbiter ruled in favor of Watson. In March 2008, Ferrlecit’s maker, Sanofi-Aventis, let Watson know that their joint agreement for supply and distribution of Ferrlecit would expire on Feb. 18, 2009, according to a filing with the U.S. Securities and Exchange Commission. Sanofi-Aventis noted it would expect damages if any sales occur after that date.

In a decision favoring Watson, the Swiss Chambers of Commerce Court of Arbitration ruled that the Ferrlecit

Save